Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Saxagliptin may maintain beta-cell function in type 1 diabetes
Last updated September 9, 2026
Key finding
The change of C-peptide max levels from baseline to 24 weeks in SAXA group was higher than in CONT group (p = 0.040).
This study evaluated saxagliptin as an adjunct to insulin therapy in type 1 diabetes. It found no significant differences in glycemic control between the two treatment groups.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated saxagliptin as an adjunct to insulin therapy in type 1 diabetes. It found no significant differences in glycemic control between the two treatment groups.
Clinical relevance
Understanding the effectiveness of adjunct therapies in managing type 1 diabetes is crucial for optimizing treatment plans. While saxagliptin did not improve glycemic control, the increase in C-peptide levels may suggest some metabolic benefits that warrant further investigation.
Keep in mind
The study may have limited generalizability due to its specific population. The sample size and duration may not be sufficient to detect long-term effects. Outcomes were primarily focused on glycemic control without assessing quality of life.
Published in
Journal Reference
Publication details and source links for this paper.
Yun S, Min S, Yong G, et al. Saxagliptin as an adjunct to insulin therapy in type 1 diabetes: a randomized controlled trial. Nutrition & Diabetes. 2026;16:5. doi:10.1038/s41387-026-00411-3
Main Effects
No differences were observed in MAGE after 24 weeks.
C-peptide max levels increased significantly in the saxagliptin group (p = 0.040).
No differences were observed in HbA1c levels after 24 weeks.
No differences were observed in insulin dosage after 24 weeks.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin only, Saxagliptin plus insulin and C-peptide, HbA1c, Insulin dosage per weight (unit/kg/day), and 1 more.
This study contributes evidence to
Primary intervention
Insulin only
Primary outcomes
- C-peptide
- HbA1c
- Insulin dosage per weight (unit/kg/day)
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
8
Evidence pairs
1074
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
C-Peptide
matched_outcome
Related evidence
Evidence topic
Glucose Variability
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin dosage per weight (unit/kg/day)
Insulin only → Insulin dosage per weight (unit/kg/day)
Insulin only → Insulin dosage per weight (unit/kg/day)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Insulin only → Mean amplitude of glycemic excursions (MAGE)
Insulin only → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin dosage per weight (unit/kg/day)
Saxagliptin plus insulin → Insulin dosage per weight (unit/kg/day)
Saxagliptin plus insulin → Insulin dosage per weight (unit/kg/day)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Saxagliptin plus insulin → Mean amplitude of glycemic excursions (MAGE)
Saxagliptin plus insulin → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- C-peptide max levels increased in the saxagliptin group (p = 0.040).
- No significant changes in HbA1c or insulin dosage were found.
- MAGE remained unchanged after 24 weeks of treatment.
Who this applies to
- Adults with type 1 diabetes receiving insulin therapy.
- Patients interested in adjunct therapies for diabetes management.
Keep in Mind
- The findings may not apply to populations outside the study's demographics.
- Long-term effects of saxagliptin were not assessed in this trial.
- The study did not evaluate the impact on patient quality of life.
Between the Lines
- The study may have limited generalizability due to its specific population.
- The sample size and duration may not be sufficient to detect long-term effects.
- Outcomes were primarily focused on glycemic control without assessing quality of life.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin only and C-peptide Levels, Insulin only and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin only → C-peptide Levels
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Insulin only → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
C-peptide Levels Evidence Hub
All studies measuring C-peptide Levels
1 studies
outcome_hubMeasures C-peptide Levels as a key outcome.
HbA1c Evidence Hub
All studies measuring HbA1c
1 studies
outcome_hubMeasures HbA1c as a key outcome.
Insulin dosage per weight (unit/kg/day) Evidence Hub
All studies measuring Insulin dosage per weight (unit/kg/day)
1 studies
outcome_hubMeasures Insulin dosage per weight (unit/kg/day) as a key outcome.
Insulin only Evidence Hub
All studies on Insulin only
1 studies
intervention_hubContributes to Insulin only evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin only and C-peptide
Intervention: Insulin onlyOutcome: C-peptide
1 results
All studies on Insulin only and HbA1c
Intervention: Insulin onlyOutcome: HbA1c
1 results
All studies on Insulin only
Intervention: Insulin only
1 results
All studies measuring C-peptide
Outcome: C-peptide
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin only improve c-peptide?
Emerging Evidence
Insulin only appears to improve c-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Saxagliptin plus insulin improve c-peptide?
Emerging Evidence
Saxagliptin plus insulin appears to improve c-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Insulin only lower HbA1c?
Emerging Evidence
Current evidence does not show a clear benefit of Insulin only for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Insulin only improve insulin dosage per weight (unit/kg/day)?
Emerging Evidence
Current evidence does not show a clear benefit of Insulin only for insulin dosage per weight (unit/kg/day).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin dosage per weight (unit/kg/day)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
High-protein diet shows little effect on glycemic control in diabetesCarbohydrate Counting Improves Estimation Skills in Type 2 DiabetesGroup-Based Education Shows No Clear Advantage for Glycemic ControlHRS-7535 improves glycemic control in adults with type 2 diabetesQCC Model Enhances Diabetes Management
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.